Recent advances in cancer vaccine research have generated renewed optimism in the field of oncology, driven by encouraging clinical results and new funding initiatives. Last week, drug makers Merck and Moderna announced that a personalized melanoma vaccine, administered after surgery, reduced the risk of cancer recurrence or death by 42 percent within two years compared to patients who did not receive the treatment. Around the same time, the U.S. National Institutes of Health (NIH) unveiled plans to invest nearly $200 million to accelerate the development of cancer vaccine therapies.

Unlike traditional vaccines that prevent infectious diseases, cancer vaccines are designed to help the immune system recognize and attack existing tumors. These vaccines work by training T cells, a type of white blood cell, to identify unique genetic markers on cancer cells and mount a targeted immune response. Most personalized cancer vaccines utilize mRNA technology, similar to that used in COVID-19 vaccines, which enables rapid customization based on a patient’s tumor genetics.

Dr. Catherine Wu, a leader in the field and head of stem cell transplantation and cellular therapies at the Dana-Farber Cancer Institute, highlighted the significance of these developments. Wu’s pioneering work nearly a decade ago demonstrated, through a small melanoma trial, that personalized cancer vaccines could induce durable immune memory that prevents recurrence. She noted that melanoma’s high mutation rate makes it particularly responsive to immune-based treatments, which is why it has served as a proving ground for vaccine approaches.

Wu described the NIH initiative as a vital boost to ongoing efforts, allowing researchers to expand personalized vaccine strategies beyond melanoma to other cancers such as blood malignancies, glioblastoma, and ovarian cancer. However, she emphasized that tumors with fewer mutations, like glioblastoma and ovarian cancer, pose greater challenges because their cells are less recognizable to the immune system. For these harder-to-target cancers, researchers must develop additional tactics to strengthen the vaccines’ effectiveness.

The Dana-Farber oncologist also discussed the limitations of cancer vaccines. They tend to work best when the tumor burden is low, such as following surgical removal of cancer, rather than in cases of widespread metastatic disease where the immune system struggles to keep pace with rapid tumor growth. Cancer vaccines may serve as powerful immune modulators but often require combination with other therapies to achieve optimal results.

Wu underscored the symbiotic relationship between cancer vaccine research and the rapid COVID-19 vaccine development, noting that foundational work on mRNA cancer vaccines helped pave the way for the successful deployment of coronavirus vaccines. Conversely, advances made during the pandemic have now reenergized efforts to bring mRNA technology back to cancer treatment.

While clinical trials for vaccines targeting difficult cancers like pancreatic and ovarian cancer are underway at academic centers, Wu stressed that broader patient access will depend on continued collaboration and research. “Everyone wants this to happen,” she said, expressing cautious optimism about the future of personalized cancer vaccines and their potential to transform cancer care.